US patent office seeks to reinstate suspended rule on application size
This article was originally published in SRA
Executive Summary
The US Patent and Trademark Office has voiced its arguments before the US Court of Appeals for the Federal Circuit in an effort to reinstate a suspended final rule that had sought to limit the size of patent applications1,2. The controversial rule was opposed by the pharmaceutical, biotech and medical technology industry associations, which feared that it would have stifled innovation and stood in the way of obtaining adequate patent protection.
You may also be interested in...
EU Regulators Explain How To Ensure Transitioned Trials Align With CTR
Members of the EU’s Clinical Trials Coordination Group have developed harmonized requirements for updating trials that are transitioned to the Clinical Trials Information System based on a minimum set of documents.
Global Medtech Guidance Tracker: March 2024
Stay current on regulatory guidelines from around the world with Medtech Insight's Guidance Tracker. Fifty-nine documents have been posted on the tracker since its last update.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.